EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma

The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open‐label studies that have confirmed enh...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Michaleas, Sotirios, Penninga, Elisabeth, Hovgaard, Doris, Dalseg, Anne‐Marie, Rosso, Aldana, Sarac, Sinan B., Jimenez, Jorge Camarero, Fernández, Lucia López‐Anglada, Fernández, Carolina Prieto, Mangas‐SanJuan, Victor, Garcia, Isabel, Payares‐Herrera, Concepcion, Sancho‐López, Aranzazu, Enzmann, Harald, de Castro Lopes Silva, Marcia Sofia Sanches, Duarte, Sílvia, Pignatti, Francesco
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Regulatory Issues: EMA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938407/
https://ncbi.nlm.nih.gov/pubmed/33026700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13554
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars